Formulary is a peer reviewed journal that provides timely, accurate, and practical drug-related information to assist our readers in their drug management responsibilities-evaluating drugs for the formulary and developing policies and procedures to guide the appropriate, rational, safe, and cost-effective use of drugs.
For Advertising, Custom Programs, and Web:Scott Handschuch
Director of Custom Programs
732-346-3077
scotth@advanstar.com
For Product & Service Showcase and Web:Carla Kastanis
Marketing Advisor
440-891-2711
ckastanis@advanstar.com
For Lists:Tamara Phillips
Marketing Advisor
440-891-2773
tphillips@advanstar.com
For contracts, insertions orders, other instructions, publication-set copy, reproduction materials, electronic file disks andproofs:Sheila Markes
Production Manager
218-740-6509
smarkes@advanstar.com
For detailed digital ad specifications and to submit your materials, click here.
FDA Approves Subcutaneous Tecentriq to Treat Multiple Cancers
September 13th 2024Tecentriq Hybreza can be administered over seven minutes, compared with 30 to 60 minutes for IV infusion of Tecentriq. There is no word yet on when Tecentriq Hybreza will be available or what the price will be.
Read More
FDA Warns of Liver Injury with Veozah for Hot Flashes
September 12th 2024The FDA has identified a probable case of serious drug induced liver injury that occurred in a woman in the United States who had received Veozah. The agency is requiring additional liver blood testing after starting therapy.
Read More